Referred to the House Committee on Energy and Commerce.
This bill amends the Federal Food, Drug, and Cosmetic Act to require that any "abortion-inducing drug" be labeled with the name and address of the dispenser and the name of the prescriber. It treats such a drug as misbranded unless the required label information appears, and it prevents states from having labeling requirements that are less stringent than this federal standard.
Privacy vs. enforcement: liberals emphasize patient/provider privacy and access harms; conservatives emphasize accountability and enforcement benefits.
Relative to its intended legislative type, this bill clearly performs a substantive amendment to the Federal Food, Drug, and Cosmetic Act by adding a labeling requirement, a statutory definition, a preemption clause, and a severability provision, but it provides limited implementation detail.
This bill amends the Federal Food, Drug, and Cosmetic Act to require that any "abortion-inducing drug" be labeled with the name and address of the dispenser and the name of the prescriber.
It treats such a drug as misbranded unless the required label information appears, and it prevents states from having labeling requirements that are less stringent than this federal standard.
The bill defines "abortion-inducing drug" broadly as a drug intended or in fact used to kill an unborn child or terminate a pregnancy, but excludes drugs intended to remove a dead unborn child or to treat an ectopic pregnancy.
On content alone, the bill is narrowly focused and administratively implementable, which helps; but it addresses a highly contentious policy area (abortion), creates potentially sensitive disclosure requirements tied to prescribers and dispensers, lacks compromise mechanisms, and is likely to provoke organized opposition and litigation. Those factors reduce the probability of surviving both chambers and any legal challenges.
Relative to its intended legislative type, this bill clearly performs a substantive amendment to the Federal Food, Drug, and Cosmetic Act by adding a labeling requirement, a statutory definition, a preemption clause, and a severability provision, but it provides limited implementation detail.
Privacy vs. enforcement: liberals emphasize patient/provider privacy and access harms; conservatives emphasize accountability and enforcement benefits.
These are examples from the analysis, not a ranked list of the most-affected groups.
Privacy vs. enforcement: liberals emphasize patient/provider privacy and access harms; conservatives emphasize accountability and enforcement benefits.
A mainstream liberal/left-leaning observer would likely view the bill as a law that threatens patient and provider privacy and could deter access to medication abortion.
They would see the label requirement as creating an easily discoverable link between patients, prescribers, and dispensers that could be used in civil or criminal investigations in states hostile to abortion.
They would be concerned the definition's breadth and the lack of explicit privacy or anti‑use protections would chill telemedicine and mail-order access and could harm marginalized patients who rely on remote care.
A centrist/moderate would see both legitimate regulatory aims (uniform labeling, traceability) and serious practical and legal concerns.
They would value a clear national standard to avoid a patchwork of rules but worry the bill's wording is vague (especially "in fact used") and that it lacks implementation and privacy safeguards.
A centrist would likely seek compromises that preserve patient confidentiality, provide clear administrative mechanisms for dispensing and labeling, and spell out enforcement limits.
A mainstream conservative would likely view the bill favorably as a measure that increases accountability and traceability for abortion medications and as a tool to enforce laws against unlawful abortions.
They would emphasize the need to link drug batches to prescribers and dispensers to prevent misuse and anonymous distribution.
Some conservatives might still question federal intrusion into labeling if they prefer state authority, but the bill's goal aligns with pro‑accountability and pro‑life priorities.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is narrowly focused and administratively implementable, which helps; but it addresses a highly contentious policy area (abortion), creates potentially sensitive disclosure requirements tied to prescribers and dispensers, lacks compromise mechanisms, and is likely to provoke organized opposition and litigation. Those factors reduce the probability of surviving both chambers and any legal challenges.
The bill has not accumulated any surfaced votes yet.
Privacy vs. enforcement: liberals emphasize patient/provider privacy and access harms; conservatives emphasize accountability and enforceme…
On content alone, the bill is narrowly focused and administratively implementable, which helps; but it addresses a highly contentious polic…
Relative to its intended legislative type, this bill clearly performs a substantive amendment to the Federal Food, Drug, and Cosmetic Act by adding a labeling requirement, a statutory definition, a preemption clause, an…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.